Linagliptin

Jun 11, 2019

Safety of Linagliptin for Adults with Type 2 Diabetes Who Have High Risk of Cardiovascular and/or Renal Disease Examined in CARMELINA

Jun 10, 2019

Linagliptin and Glimepiride Have Comparable Cardiovascular Safety Effects in Type 2 Diabetes at High Cardiovascular Risk

Jun 04, 2019

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Oct 17, 2018

Global DPP-IV Inhibitors Markets 2016-2024 by Drugs (Sitagliptin, Vildagliptin, Saxagliptin & Others) & Segments (Sitagliptin, Saxagliptin, Linagliptin & Alogliptin)

Oct 04, 2018

Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial

Jul 19, 2018

Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint

Nov 07, 2017

Medical Affairs Reputations: Type 2 Diabetes Mellitus (EU5)

Jun 01, 2017

Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions®